


- INA-8
- ARD
- NCI-H929
- ARK
- L363
- MM-1S-Bcl-2
- LP-1
- MM-1S
- MM-1S-myr-Akt
- MM-1R
- OPM-1
- EJM
- OCI-Mys
- MM-1S-TR-15
- KMS-12-BM
- RPMI-8226/S
- U266
| MR20 | OCI-Mys7 |
| LR5 | Brown |
| Dox40 | Dox40 |
| XG-1 | XG-1 |
| LR5 | LR5 |
| DHL-10 | DHL-10 |
| DHL-4 | DHL-4 |
| DHL-7 | DHL-7 |
| DHL-8 | DHL-8 |
| RL | RL |
| WM-WSU | WM-WSU |
| GDM-1 | GDM-1 |
| HL-60 | HL-60 |
| KG-1a | KG-1a |
| REH | REH |
| BHP-10 | BHP-10 |
| BHP-17 | BHP-17 |
| BHP-2 | BHP-2 |
| SW-579 | SW-579 |
| TT | TT |
| WRO | WRO |
| ARO | ARO |
| FRO | FRO |
| ZR-75-1 | ZR-75-1 |
| MCF-7 | MCF-7 |
| MDA-MB-231 | MDA-MB-231 |
| PC-3 | PC-3 |
| LNCaP | LNCaP |
| DU145 | DU145 |
| 786-O | 786-O |
| ACHN | ACHN |
| SW480 | SW480 |
| SKOV-3 | SKOV-3 |
| TC108 | TC108 |
| TC71 | TC71 |
| TC268 | TC268 |
| TC248 | TC248 |
| WERI | WERI |



A	Control
B	αIR3
C	NVP-ADW742
D	anti-IL-6R
E	20% serum
F	αIR3+20%serum
G	NVP-ADW742+20%serum
H	anti-IL-6R+20%serum

Figure 2




a*b**c*

Figure 3






Figure 4




Figure 5




Figure 6





Fig 7

a



b




Figure 8





Fig. 9




Figure 10

Transcriptional signature of IGF-1 stimulation

	Upregulated	Downregulated
Cell signaling	CK-1 and -2, chemokine-like factor 1, CXCR-4, Aurora-1, Aurora-2, SAK, SGK, PP2A, some PP1 subunits, PP4, GADD- α and - β , PTEN, CD71	FLIP, c-raf1 (but upregulated at protein level), Gas6, IGF-1, IGF-1R, IGF-2R, IFN- α , b, omega receptor, IL-2R γ , gp130, RAR- α , RAR- γ , BCMA, TNF- α -induced protein
Apoptosis regulation	Survivin, Bad, PCD5, PCD8, PCD10, VDAC3	Bcl-2 (no effect on protein level on short- to mid-term stimulation), Mcl-1 (stable protein levels), TOSO
Cell cycle control	Ki-67, CDC -2, -5, -6, -7, -20, -23, -25, -28, -45, cyclins A2, B1, B2, E1, F, G1, (D1, D2, D3), CDK2, CDK4, PCNA, replication factor C (multiple subunits), replication proteins A1, A2, and A3, ASK, CHK1, G2-S-expressed 1, stathmin/oncoprotein 1, Wee1+	
Microenvironmental interactions	RHAMM, Integrin α E, ADAM-8, -22, -28	Integrin α 8, α L, β 1, β 5
Wnt signaling pathway		Frizzled-related protein, WNT10B, WNT5B
Transcriptional/translational control	ATF-1, ATF-3, E2F-3, eIF-1, -2, -3, -4 and -5, multiple ribosomal proteins, DP-1, c-myb, XBP-1	c-myc
DNA synthesis/repair enzymes	BUB1, BUB3, DNA-PK, deoxycytidine kinase, deoxythymidylate kinase, DHFR, dyskerin, dUTP pyrophosphatase, MCM 2, 3, 4, 5, 6, 7, MSH-2, -3, -6, RAD51, guanine monophosphate synthase, RRM1, RRM2, TOPBIIA, XRCC	
Histone regulation	HDAC1, HAT1	
Oncogenes	DEK, liposarcoma fusion gene t(12;16), SET translocation	
Heat shock proteins / Chaperones	Hsp90, -70, 105, 27, 110, 14-3-3, chaperonin TCP1	
Immune system interactions		MHC class IE and II (less extensive changes in comparison to IL-6 or co-Cx)
Nucleocytoplasmic transport and other carrier proteins	Exportin, nucleoporins 50, 54, 62, 88, 98, 155, karyopherins b1, b3, a1, a2, a3, a4, kinesin-like 1, 2, 4, 5, 6, 7 (multiple Rab, Ran proteins), transportins	
Metabolism	F0F1 ATPase mitochondrial, ornithine decarboxylase, HMG-CoA reductase, catmodulin-1 and -2	
Ubiquitin/Proteasome pathway	POH, Multiple 26S subunit genes (26S subunits α 1, α 2, α 3, α 5, α 7, β 1, β 2, β 3, β 5, β 6, β 7, β 8, ATPase 1, 2, 3, 4, 5, 6, non-ATPase 1, 2, 4, 7, 8, 11, 12, 13), UCEs, USPs	Some USPs (-9, -11)




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19





Figure 20



21/30

Figure 21




Figure 22




Figure 23




Figure 24




Figure 25





Figure 26






Figure 27

Figure 28




Figure 29






Figure 30

**ADW742**

**5-(3-Benzyloxy-phenyl)-7-(3-pyrroli
din-1-ylmethyl-cyclobutyl)-7H-pyrro
lo[2,3-d]pyrimidin-4-ylamine**

**AEW541**

**7-(3-Azetidin-1-ylmethyl-cyclobutyl
)5-(3-benzyloxy-phenyl)-7H-pyrrolo
[2,3-d]pyrimidin-4-ylamine**

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.